Following its most successful year to date, Aesica Pharmaceuticals is set to almost double in size and has successfully expanded into new markets. The company’s vision is to become the world’s leading supplier of Active Pharmaceutical Ingredients and Formulated Products and recent developments could enable Aesica to achieve this, and quickly.
As one of the fastest growing companies in the UK, Aesica has increased turnover by over 300 per cent in the last five years and was ranked 3rd in Deloitte’s 2011 Buyout Track 100 as published in The Sunday Times.
2010 was also a year of significant expansion for Aesica, as it acquired Nottingham-based R5 Pharmaceuticals in June and more recently announced the acquisition of three European sites from leading Belgian pharmaceutical firm, UCB. In addition, new business development managers were recruited for San Diego and New York in preparation for further expansion across America.
The European acquisitions, which include a long-term strategic partnership with UCB, have resulted in Aesica doubling its workforce to approximately 1,300 staff and will have a significant impact on revenue. As a result of this and planned future developments, by 2013 Aesica predicts sales of £300 million.
Dr. Robert Hardy, Chief Executive, Aesica, says: “Since Aesica was founded in 2004 we have worked strategically to expand our offering and market reach while consolidating our existing client portfolio. While we have experienced rapid growth, the contract manufacturing market also continues to experience significant growth and increasing numbers of pharmaceutical and biotechnology companies are recognising the benefits of outsourcing their drug manufacturing requirements. As companies look for greater flexibility, swifter commercialisation, minimal capital expenditure and lower scale up costs, our expertise and proven track record in delivering a full service offering is enabling us to further increase our market share and reach new markets.
While contract manufacturers are broadening their service offering to cover development, regulatory advice, manufacturing and packing, to manage the whole product lifecycle, we have offered such service provision from the outset. Now we are looking at new ways of adding value to our offering through the development of new high containment facilities to complement our high potency capability. Such evolution and development is critical to ensuring we are at the forefront of our industry and effectively shaping market trends.
Our vision has always been to become the leading supplier of Active Pharmaceutical Ingredients and Formulated Products to the global pharmaceutical and biotechnology industries and following the success of 2010 we have secured a greater market share, taking us one step closer to achieving this ambition.
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.
Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within the company enables it to provide primary and secondary contract manufacturing services to the highest possible standards. It is this all-encompassing offer and its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.